Cargando…

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs

BACKGROUND AND OBJECTIVE: We have previously reported that BRCA2 N372 H i.a.1342A>C heterozygous variation presented in platinum-resistant patients. This study aimed to further investigate the mechanism of BRCA2 N372 H mutation in the development of platinum resistance in ovarian cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Zhen-Hua, Xia, Yu, Yang, Qing, Gao, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768310/ https://www.ncbi.nlm.nih.gov/pubmed/33357097 http://dx.doi.org/10.1177/1533033820983289

Ejemplares similares

BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls
por: Su, Liangxiang, et al.
Publicado: (2015)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

Selection of Pathological N0 (pN0) in Clinical IA (cIA) Lung Adenocarcinoma by Imaging Findings of the Main Tumor
por: Kanamoto, Yasuyuki, et al.
Publicado: (2020)

Association of BRCA2 N372H polymorphism with cancer susceptibility: A comprehensive review and meta-analysis
por: Xue, Wen-Qiong, et al.
Publicado: (2014)

BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
por: Unni, Sudhir K., et al.
Publicado: (2016)

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis
por: Salwa, Amreen, et al.
Publicado: (2021)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

High-Affinity α-Conotoxin PnIA Analogs Designed on the Basis of the Protein Surface Topography Method
por: Kasheverov, Igor E., et al.
Publicado: (2016)

P1342: THE IMPACT OF CLONAL HEMATOPOIESIS ON THE RISK OF SEVERE COVID-19 INFECTION
por: Saiki, Ryunosuke, et al.
Publicado: (2023)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

1342. Clinical failure rates of amoxicillin for the treatment of acute otitis media in young children
por: Frost, Holly M, et al.
Publicado: (2020)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
por: Rubio Pérez, María Jesús
Publicado: (2017)

THU372 Finasteride Induced Hyperglycemia
por: Bose, Vivek, et al.
Publicado: (2023)

Sexual assault and abuse committed against family members: An analysis of 1342 legal outcomes and their motivations
por: Blandino, Alberto, et al.
Publicado: (2021)

Atomic and electronic structure of solids of Ge(2)Br(2)PN, Ge(2)I(2)PN, Sn(2)Cl(2)PN, Sn(2)Br(2)PN and Sn(2)I(2)PN inorganic double helices: a first principles study
por: Bijoy, T. K., et al.
Publicado: (2020)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
por: Majić, Ana, et al.
Publicado: (2020)

The new impact factor of International Brazilian Journal of Urology is 1.342. Where can we get?
por: Favorito, Luciano A.
Publicado: (2020)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
por: Ma, Jiao, et al.
Publicado: (2019)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Assessment of Clinical Stage IA Lung Adenocarcinoma with pN1/N2 Metastasis Using CT Quantitative Texture Analysis
por: Zhu, Haixu, et al.
Publicado: (2020)

NCLEX-PN®
por: Gardner, Wilda
Publicado: (2017)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Bismuth Amides Mediate Facile and Highly Selective Pn–Pn Radical‐Coupling Reactions (Pn=N, P, As)
por: Oberdorf, Kai, et al.
Publicado: (2021)

I.A. Golutvin (Dubna)
por: CERN PhotoLab
Publicado: (1975)

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2017)

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Annellated 1,3,4,2-Triazaphospholenes-Simple Modular Synthesis and a First Exploration of Ligand Properties
por: Richter, Ferdinand, et al.
Publicado: (2022)

Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy
por: Palli, Domenico, et al.
Publicado: (2007)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum
por: Yew, Kok-Hooi, et al.
Publicado: (2013)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2020)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_84pvlm45fbtfdtmbn343hs96c4